Posted by Chairman_MAO on May 12, 2009, at 15:43:45
Check out this abstract that I found ...
I've been taking 200mcg of chromium
picolinate with each dose of Nardil,
and it really seems to help curb
carbohydrate cravings. There's no particular
rationale for my taking it four times per day
other than it matches when I take the
Nardil.I had a glucose tolerance test done once; the
result was, if I recall correctly, that I was
almost clinically hypoglycemic. On the other
hand, according to Wikipedia, anyway, an oral glucose
tolerance test is anything but robust. I was not
on Nardil when this test was done.Has anyone tried chromium supplementation
with Nardil?--Chairman_MAO
J Clin Psychiatry. 1997 Jun;58(6):274.
Treatment of depression in patients with diabetes mellitus.
Goodnick PJ, Henry JH, Buki VM.
Department of Psychiatry, University of Miami, FL 33136, USA.
BACKGROUND: Depression occurs frequently in patients with diabetes mellitus.
Little has been published on the epidemiology, biochemistry, and treatment of
depression in diabetic patients. METHOD: We searched MEDLINE for literature fromJanuary 1966 to July 1993 and cross-referenced the terms diabetes, glucose,
hyperglycemia, or hypoglycemia, with each of the following: antidepressants,
monoamine oxidase inhibitors, tricyclic antidepressants, fluoxetine, paroxetine,sertraline, and bupropion. The results reviewed were 20 papers on epidemiology,
15 papers on neurochemicals and glucose control, and 28 papers on antidepressants
and factors of importance to diabetics. Additional papers were selected from thereference lists of the retrieved articles. RESULTS: The prevalence of depression
in diabetics varies from 8.5% to 27.3%. Severity of depression correlates strongly with many symptoms of diabetes mellitus. The hydrazine monoamine oxidaseinhibitors (MAOIs), e.g., phenelzine, potentiate animal models of hypoglycemia
due to direct influence on gluconeogenesis secondary to the hydrazine structure,
not to MAOI considerations. Dopamine and norepinephrine influences in thesemodels appear to be hyperglycemic. Serotonergic influences, in the presence of
MAOIs, which decrease serotonin metabolism, are in contrast hypoglycemic.
Clinically, MAOI use is limited by the possible severity of the induced
hypoglycemia, induced weight gain, and required diets.
poster:Chairman_MAO
thread:895390
URL: http://www.dr-bob.org/babble/20090505/msgs/895390.html